TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Frontline treatment with BV+CHP demonstrated superiority to CHOP in terms of a statistically significant improvement in PFS and OS in patients with CD30‐positive PTCL and had a good safety profile.